RXBIO INC
Grant: $231,011 - National Institutes of Health - Jul. 27, 2009
No votes have been cast for this award yet
Join the conversation: Post a comment about this award
Award Description: The Gastrointestinal (GI) mucosa is one of the most radiosensitive tissues, and radiation-associated GI injury could be fatal. Supported by grant 1RC1AI078512-01, we have demonstrated that Rx100 is a potent radiomitigator in the GI tract with a dose-modification factor of 1.2. In this supplement application supplement to grant we propose to expand studies on Rx100 to generate additional data required for an Investigational New Drug filing with the FDA. This supplement will accelerate the IND filing.
Project Description: Project is underway. Initial supplies have been ordered and received. We await invoices for same. Expenditures to date have been for salaries, fringe benefits, and F&A.
Jobs Summary: To date, this funding has allowed us to hire one technician and retain two scientists. (Total jobs reported: 3)
Project Status: Less Than 50% Completed
This award's data was last updated on Jul. 27, 2009. Help expand these official descriptions using the wiki below.
No comments have been added for this project.